Skip navigation

Practical Strategies for Direct Contracting, Hospital Sales and Data Utilization to Drive Product Success in Evolving Health Systems

August 16-17, 2017
  • Philadelphia, PA

As health systems continue to grow and consolidate to form major Integrated Delivery Networks (IDNs), manufacturers are tasked with learning how to best contract with, and sell to, these evolving systems to ensure product success. With conflict of interest policies in place and restricted access to physicians, manufacturers are changing their sales approach to better reach and engage these new customers. CBI’s Partnering with IDNs Strategy Summit convenes manufacturers and IDNs to discuss how to create a mutually beneficial partnership that contributes to continual care coordination,
strategic product management and enhanced access.

CLE Credits
Available! Pending Approval


  • Forecasting the 2- and 5-year outlook for IDNs and the overall
    healthcare ecosystem
  • The impact of current biologic and biosimilar legislation and regulations (biosimilar naming, state substitution, reporting) on Healthcare Information Technology (HIT) used by integrated delivery networks
  • How drug choice impacts speed-to-fill and how specialty pharmacy stewardship affects patient outcomes
  • Choosing the right partners for your brand and identifying the key decision-makers
  • How to overcome the challenges of limited access to physicians in
    certain networks
  • What becoming more “customer-centric” actually means for manufacturers
  • Best practices and opportunities for measuring success in the IDN channel
  • Establishing Partnerships with IDNs to Affect the Patient Journey and Outcomes
  • Optimize Patient Care through Integration and Collaboration
  • Gain Insights into Provider Care Coordination and
    Population Health Management
  • Follow the Patient Journey through an IDN
  • From Diagnosis to Delivery —
    Disruptive Innovation in a Specialty Pharmacy

Previous Attendee Acclaim:

A forward-thinking conference grounded in real reasons for
the change. This conference could easily expand to 10 times
its current size as these changes take hold.

Director, Team Leader, U.S. Payer & Channel Access, Pfizer Inc

Our company is new to exploring IDNs. This conference was an amazing way to learn more about the landscape and understand how others are attempting to engage this ‘new’ target.

Director, Managed Markets, Grifols

Great opportunity to hear peers from all aspects of the IDN
to see the holistic picture.

Senior Director, Acentrus

Well planned content from experts that will help me create
a strategy in this space.

Account Executive-Biopharm, Novo Nordisk

Great interaction between stakeholders.

Vice President, Acentrus

August 16-17, 2017 Wyndham Historic District Philadelphia, PA